Frequently Asked Questions

Q. What does Oxygen Biotherapeutics, Inc. do?
A. Oxygen Biotherapeutics, Inc., is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine™. The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (OXYCYTE™) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. The company believes OXYCYTE has the potential for use in multiple indications, including traumatic brain injury, sickle cell crisis pain, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes and cosmetic applications.

Q. When was Oxygen Biotherapeutics established?
A. Synthetic Blood International, Inc. was established in 1990. The company changed its name to Oxygen Biotherapeutics, Inc. on July 1, 2008.

Q. When does Oxygen Biotherapeutics, Inc.'s fiscal year end?
A. April 30

Q. On which exchange does Oxygen Biotherapeutics trade and what is the symbol?
A. Oxygen Biotherapeutics trades on the NASDAQ. The ticker is OXBT.

Q. When did Oxygen Biotherapeutics become public?
A. The company became public under the name Synthetic Blood International, Inc. in November 1990.

Q. How many shares are outstanding?
A. As of March 15, 2010, there were 21,310,748 shares outstanding.

Q. Does Oxygen Biotherapeutics issue dividends on its common stock?
A. No.

Q. Does Oxygen Biotherapeutics have a Direct Stock Purchase Plan or Dividend Reinvestment Plan (DRIP)?
A. No.

Q. Who is Oxygen Biotherapeutics's independent auditor?
A.Cherry, Bekaert & Holland LLP
2626 Glenwood Avenue
Raleigh, NC 27608

Q. Who is Oxygen Biotherapeutics's stock transfer agent?
A. Interwest Transfer Co.
1981 E. 48 South, Suite 100
P.O. Box 17136
Salt Lake City, UT 84117
Phone: (801) 272-9294
Fax: (801) 277-3147
www.interwesttc.com

Q. How do I contact Oxygen Biotherapeutics’s Investor Relations?
A. Please call Abe Wischnia & Associates at (619) 795-2345.
Information requests can be made online via the information request form

Q. Where are Oxygen Biotherapeutics's headquarters?
A. Oxygen Biotherapeutics, Inc
2530 Meridian Pkwy, 3rd floor
Durham, NC 27713

  • Funds breathe new life into Oxygen Biotherapeutics

By DAVID RANII
Posted on Wednesday, Jan. 25, 2012

After a tumultuous year that featured the dismissal of its CEO, drug-development company Oxygen Biotherapeutics is starting 2012 in its best financial shape in years.
The small, publicly traded Morrisville company turned a financial corner at the end of last year when it sold $7.5 million in preferred stock and warrants to institutional investors. The company received $3.5 million in December, with the second installment expected midyear.

In the past, Oxygen Bio has raised money that would carry it forward for about six months, but this was a richer deal. More...

NEW VIDEO

This new video looks at Oxycyte™ as a potential treatment for Traumatic Brain Injury and Decompression Sickness.